Why the study?
Obesity is linked to cardiovascular diseases and metabolic disorders, motivating an evaluation of changes and correlations among serum omentin-1, lipid profiles, trace elements, and insulin resistance across prediabetic obese patients, healthy obese, and control subjects.
Are omentin-1 levels and trace elements altered in prediabetic obese patients compared to healthy obese and control subjects?
Are omentin-1 levels and trace elements altered in prediabetic obese patients compared to healthy obese and control subjects?
Omentin-1 levels are decreased in prediabetic obese patients and inversely correlate with insulin resistance, suggesting its potential as a biomarker for obesity-related metabolic disorders.
Answers are grounded in this paper and cite their sources.
Omentin-1 and metabolic shifts in prediabetic obesity may signal risk; leaves open biomarker utility pending validation.
The obesity is one of the most common physiological disorders, also it is linked with a variety of circumstances like hypertension, dyslipidemia, T2DM, non-alcoholic fatty liver disease, and cardiovascular diseases. The aim of this study was to check the changes and compare serum omentin-1, lipid profile (TC, TG, VLDL-C, LDL-C, and HDL-C), trace elements (Mg, Zn, Cu, Fe) and insulin resistance between the prediabetic obese patients, healthy obese, and control subjects and assess the correlation between omentin-1, lipid profile, trace elements (Mg, Zn, Cu, Fe) levels and insulin resistance in prediabetic obese patients. Correlation analysis between omentin-1 levels with the biochemical parameters in the prediabetic obese patients with WC, body mass index, FBG, Insulin, HOMA-IR, HbA1c, TG, TC, LDL-C, VLDL-C, and copper was found to be negative; while significant positive correlation of omentin-1 with HDL-C, Mg, Zn, and Fe was noticed. Omentin-1 serum concentration level decrease and insulin resistance increased in prediabetic obese patients compared to healthy obese and control individuals. Omentin-1 inversely associated with obesity and insulin resistance, therefore can be used as a biomarker for obesity related metabolic disorders.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: